Pluristem Therapeutics, a leading developer of placenta-based cell therapies, announced that its senior scientists will present updated developments relating to the company’s proprietary 3D cell expansion technology at the Scale-Up and Manufacturing of Cell-Based Therapies II Conference in San Diego, California, which is being held January 21-23, 2013. These innovations will be implemented in Pluristem’s new state-of-the-art manufacturing facility for expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs).
The following presentations will be made by Pluristem’s team:
• “Bioreactors in Cell Therapy, the Advantages of High-Throughput Culturing Technologies and the Downstream Challenges” – Ohad Karnieli PhD, MBA and VP of Development at Pluristem, will present Pluristem’s new production line and demonstrate how the company has utilized high-throughput culturing to solve many of the problems related to the mass production of ASCs. Dr. Karnieli’s presentation will be made available at the company’s website .
• “From Gene Expression to In Vivo Models – Characterization and Potential Therapeutic Properties of Placenta Derived Mesenchymal-Like Adherent Stromal Cells” – Eytan Abraham, PhD and Product Innovation Research Manager, will address the specific changes that occur in gene regulation and protein secretion when ASCs are grown in a 3D culturing phase and the biological changes and therapeutic advantages of implementing this technology in the mass expansion of ASCs use.
Pluristem Therapeutics, a leading developer of placenta-based cell therapies, has a robust patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. Pluristem is focusing on the development of PLX (PLacental eXpanded) cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.
For more information, visit www.pluristem.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.comwww.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
